Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

BACKGROUND: Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations. Once resistance emerges, targeting KIT with tyrosine kinase inhibitors (TKIs) sunitinib a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Serrano, César, Mariño-Enríquez, Adrián, Tao, Derrick L., Ketzer, Julia, Eilers, Grant, Zhu, Meijun, Yu, Channing, Mannan, Aristotle M., Rubin, Brian P., Demetri, George D., Raut, Chandrajit P., Presnell, Ajia, McKinley, Arin, Heinrich, Michael C., Czaplinski, Jeffrey T., Sicinska, Ewa, Bauer, Sebastian, George, Suzanne, Fletcher, Jonathan A.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6462042/
https://ncbi.nlm.nih.gov/pubmed/30792533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0389-6
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker